Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
Price : $35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 25 Nov 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 Oct 2014 Planned initiation date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 17 Oct 2014 New trial record